8:30 – 10:30 am – “Cannabis and CBD in 2023”
Cannabis policies are constantly changing. Many of our patients are either interested in using cannabis
or cannabinoids or are already doing so. In this seminar, Dr. Hill will review the evidence for both the
risks and the benefits of cannabis and cannabinoids like CBD so that healthcare professionals can help
patients make more informed choices about using these complex substances.
LEARNING OBJECTIVES
1. To review some of the basic risks associated with cannabis use.
2. To discuss the current state of the evidence for the therapeutic use of cannabis.
3. To describe potential side effects of CBD.
Speaker: Kevin P. Hill, MD, Beth Isreal Deaconess Medical Center, Harvard Medical School

10:30 – 10:45 am Break

10:45 – 11:45 am “Medical Management of Hypersexual Behaviors”
Hypersexual behaviors are not uncommon in psychiatric clinical settings. In this presentation, Dr.
Stanislaus will discuss the role of hormones and neurotransmitters in sexual behaviors, the medications
that have clinical utility in managing hypersexual behaviors and their pharmacological actions.
LEARNING OBJECTIVES
1. Understand the role of sex hormones and neurotransmitters in sexual functioning.
2. Understand the role of medications in managing hypersexual behaviors.
3. Learn the mechanism of action of the various classes of medications in decreasing hypersexual
behaviors.
Speaker: Angeline Stanislaus, MD, Forensic Psychiatrist, Chief Medical Officer, Missouri Department of
Mental Health

11:45 – 12:00 noon Break

12:00 – 1:00 pm “Psychedelics 102: Psychedelic-Assisted Psychotherapy”
The presentation will cover a brief history of psychedelics in America, how we got to this point in
research and clinical use, concepts of neuroplasticity and synaptogenesis, elements of psychedelicassisted psychotherapy and how they differ from traditional psychotherapy.
LEARNING OBJECTIVES
1. Know the difference between traditional and psychedelic-assisted psychotherapy.
2. Know the basic categories of psychedelics currently being studied and used clinically.
3. Know who may be appropriate for this type of therapy.
Speaker: Larry Shapiro, PhD, Quantum Behavioral, LLC, Washington University School of Medicine